• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Zymeworks Inc.

    3/6/26 9:00:02 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001604800
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Zymeworks Inc.
    SEC File Number
    001-41535
    Address of Issuer
    108 Patriot Drive, Suite A
    Middletown
    DELAWARE
    19709
    Phone
    302-274-8744
    Name of Person for Whose Account the Securities are To Be Sold
    Jeffrey T L Smith
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Morgan Stanley Wealth Management Canada
    140 4th Ave. SW, Suite 2740
    Calgary � A0 � T2P 3N3
    2473336133858.407374960703/06/2026
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock03/06/2026Exercise of OptionsIssuerCheckbox not checked22062503/06/2026Exercise and sell to cover
    Common Stock01/12/2026Vesting of Restricted Stock UnitsIssuerCheckbox not checked835601/12/2026Compensation
    Common Stock01/05/2026Vesting of Restricted Stock UnitsIssuerCheckbox not checked946201/05/2026Compensation
    Common Stock01/05/2025Vesting of Restricted Stock UnitsIssuerCheckbox not checked889001/05/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Jeffrey T L Smith
    c/o Zymeworks Inc.
    108 Patriot Drive, Suite A
    Middletown, � DE � 19709
    Common Stock01/05/202610538264471.13
    Jeffrey T L Smith
    c/o Zymeworks Inc.
    108 Patriot Drive, Suite A
    Middletown, � DE � 19709
    Common Stock01/12/20269310211090.28

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/06/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jeffrey T L Smith

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ZYME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    10/24/2025$15.00Equal Weight
    Wells Fargo
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    10/10/2025$30.00Buy
    B. Riley Securities
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

    Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple solid tumor models New programs include Ly6E, CLDN18.2, and PTK7-targeting ADCs, as well as novel payload and platform innovations New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherape

    4/17/26 3:00:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

    VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr

    4/16/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

    • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e

    4/9/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Zymeworks with a new price target

    Wells Fargo resumed coverage of Zymeworks with a rating of Equal Weight and set a new price target of $15.00

    10/24/25 9:02:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schayowitz Adam

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/10/26 4:10:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Platshon Scott

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/10/26 4:10:03 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Platshon Scott

    3 - Zymeworks Inc. (0001937653) (Issuer)

    4/10/26 4:05:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Zymeworks Inc.

    SCHEDULE 13G - Zymeworks Inc. (0001937653) (Subject)

    4/15/26 4:16:19 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Zymeworks Inc.

    8-K - Zymeworks Inc. (0001937653) (Filer)

    4/1/26 6:16:43 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Zymeworks Inc.

    144 - Zymeworks Inc. (0001937653) (Subject)

    3/6/26 9:00:02 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/18/25 3:17:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/7/25 6:34:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

    • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e

    4/9/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Kristin Stafford as Chief Financial Officer

    VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a

    4/1/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

    VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati

    11/18/25 1:01:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Financials

    Live finance-specific insights

    View All

    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

    VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr

    4/16/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed

    3/2/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

    VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET). About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a

    2/12/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 4:27:20 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zymeworks Inc.

    SC 13G - Zymeworks Inc. (0001937653) (Subject)

    11/13/24 4:30:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care